PHAT News - Candlesense

Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences

FLORHAM PARK, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gast...

Investor

3 days ago

Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing

FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be fi...

Ownership

8 days ago

Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates

FLORHAM PARK, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gast...

What is the projected impact on the company’s cash runway and capital‑raising needs going forward? How does this earnings release affect analyst consensus target prices and rating changes? What risk factors were highlighted in the earnings release that could influence the near‑term outlook or stock volatility?

Earnings

21 days ago